Replimune Group, Inc. (REPL) - Dilution Analysis

S-3/A filing: The company is filing an S-3/A to offer and sell up to $250 million in the aggregate of shares of common stock, preferred stock, warrants and debt securities, as well as units that include any combination of the foregoing securities.

10-Q filing | 78.4M shares outstanding

S-3 filing: This S-3 filing registers 25,103,489 shares of common stock for resale by selling stockholders.

S-3 filing: The company intends to offer and sell up to $250 million in the aggregate of shares of our common stock, shares of preferred stock, warrants and debt securities, as well as units that include any combination of the foregoing securities.

10-K filing | 80.6M shares outstanding

10-Q filing | 83.5M shares outstanding

8-K filing: Replimune Group, Inc. completed an offering of 6,923,000 shares of common stock and pre-funded warrants to purchase 3,846,184 shares, with the underwriter exercising their option to purchase an additional 1,615,377 shares, at a price of $13.00 per share and $12.9999 per pre-funded warrant, estimating net proceeds of $155.8 million.

10-Q filing | 68.4M shares outstanding

S-3 filing: Replimune Group, Inc. files an S-3 to register the resale of up to 11,338,515 shares of common stock by selling stockholders.

10-Q filing | 69.2M shares outstanding

8-K filing: Replimune Group, Inc. entered into a securities purchase agreement for a private placement of shares of common stock and pre-funded warrants with certain institutional and accredited investors, expected to close on June 14, 2024. ($99.99M proceeds)

POS AM filing: This POS AM filing relates to the potential offering and sale of up to $250 million in the aggregate of shares of common stock, preferred stock, warrants, debt securities, and units, as well as an at the market offering of common stock with an aggregate offering price of up to $100 million.

10-K filing | 66.6M shares outstanding

10-Q filing | 66.6M shares outstanding

10-Q filing | 59.1M shares outstanding

10-Q filing | 59.0M shares outstanding

10-K filing | 58.2M shares outstanding

10-Q filing | 57.9M shares outstanding

8-K filing: Replimune Group, Inc. completed an offering of 5,374,486 shares of common stock and pre-funded warrants to purchase 4,200,000 shares, with the underwriters exercising their option to purchase an additional 1,436,172 shares, resulting in estimated net proceeds of $242.6 million.

10-Q filing | 49.7M shares outstanding

10-Q filing | 54.2M shares outstanding

S-3 filing: The company is filing a shelf registration statement to offer and sell shares of common stock, shares of preferred stock, warrants and debt securities, as well as units that include any combination of the foregoing securities, with an aggregate offering price of up to $400 million.

10-K filing | 52.2M shares outstanding

10-Q filing | 47.2M shares outstanding

10-Q filing | 46.9M shares outstanding

10-Q filing | 46.8M shares outstanding

10-K filing | 46.6M shares outstanding

10-Q filing | 46.5M shares outstanding

10-Q filing | 46.0M shares outstanding

8-K filing: Replimune Group, Inc. completed an offering of 4,687,500 shares of common stock and pre-funded warrants to purchase 1,562,500 shares, with underwriters exercising their option to purchase an additional 937,500 shares at $40.00 per share, resulting in estimated net proceeds of $270.0 million. ($262.5M proceeds)

S-3 filing: The filing is an S-3 form for a shelf offering of common stock, preferred stock, warrants, debt securities, and units up to an aggregate offering price of $350,000,000, and also details an at-the-market offering of common stock up to $75,000,000.

10-Q filing | 40.3M shares outstanding

8-K filing: Replimune Group, Inc. issued and sold an additional 652,173 shares of its common stock to the underwriters for $23.00 per share, representing the full exercise of the underwriters' option. The company also issued and sold an aggregate of 3,478,261 shares of its common stock and pre-funded warrants to purchase 1,521,738 shares, resulting in approximately $115.0 million in gross proceeds. ($115.0M proceeds)

8-K filing: Replimune Group, Inc. entered into an underwriting agreement for the issuance and sale of 2,826,088 shares of common stock and pre-funded warrants to purchase 1,521,738 shares of common stock at a public offering price of $23.00 per share and $22.9999 per pre-funded warrant, respectively, with estimated net proceeds of approximately $93.7 million.

8-K filing: Replimune Group, Inc. amended its Sales Agreement with SVB Leerink LLC to reduce the aggregate offering amount of its ATM Offering from $75,000,000 to $30,000,000, which includes approximately 287,559 shares of common stock already sold for gross proceeds of approximately $4.6 million. ($4.6M proceeds)

10-K filing | 36.8M shares outstanding

10-Q filing | 36.6M shares outstanding